Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Change in Acquisitions & Divestments (2016 - 2019)

Historic Change in Acquisitions & Divestments for Lifecore Biomedical, Inc. \De\ (LFCR) over the last 10 years, with Q4 2019 value amounting to $68000.0.

  • Lifecore Biomedical, Inc. \De\'s Change in Acquisitions & Divestments fell 6512.82% to $68000.0 in Q4 2019 from the same period last year, while for Aug 2020 it was $68000.0, marking a year-over-year decrease of 9191.44%. This contributed to the annual value of $364000.0 for FY2020, which is 3321.1% down from last year.
  • According to the latest figures from Q4 2019, Lifecore Biomedical, Inc. \De\'s Change in Acquisitions & Divestments is $68000.0, which was down 6512.82% from $296000.0 recorded in Q3 2019.
  • In the past 5 years, Lifecore Biomedical, Inc. \De\'s Change in Acquisitions & Divestments registered a high of $4.4 million during Q1 2015, and its lowest value of $68000.0 during Q4 2019.
  • Its 4-year average for Change in Acquisitions & Divestments is $813625.0, with a median of $221000.0 in 2016.
  • In the last 5 years, Lifecore Biomedical, Inc. \De\'s Change in Acquisitions & Divestments plummeted by 9466.09% in 2016 and then crashed by 6512.82% in 2019.
  • Over the past 4 years, Lifecore Biomedical, Inc. \De\'s Change in Acquisitions & Divestments (Quarter) stood at $1.0 million in 2015, then tumbled by 76.77% to $233000.0 in 2016, then fell by 16.31% to $195000.0 in 2018, then tumbled by 65.13% to $68000.0 in 2019.
  • Its Change in Acquisitions & Divestments was $68000.0 in Q4 2019, compared to $296000.0 in Q3 2019 and $141000.0 in Q2 2019.